



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 08 Aug 2022 (#31)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

**Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)**

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Important Notices

[NOT-OD-22-189](#) **Implementation Details for the NIH Data Management and Sharing Policy.** The purpose of this notice is to inform the extramural research community of implementation details for the [NIH Policy for Data Management and Sharing \(DMS Policy\)](#) affecting grant and cooperative agreement applications submitted for receipt dates on or after January 25, 2023. The specific changes to competing grant and cooperative agreement application instructions clarified below will be implemented with application form packages identified with a Competition ID of "FORMS-H" and incorporated into the forthcoming FORMS-H application guides. Although the DMS Policy will apply also to Research and Development (R&D) contracts, NIH intramural research projects, and other funding agreements (e.g., Other Transactions), the forms changes and other implementation details provided in this Notice apply only to NIH extramural grant and cooperative agreement activities. Details applicable to R&D contracts will be incorporated into the appropriate Requests for Proposals, and details applicable to Other Transactions will be incorporated into the appropriate Research Opportunity Announcement.

[NOT-OD-22-190](#) **Adjustments to NIH and AHRQ Grant Application Due Dates Between September 22 and September 30, 2022.** This notice informs the community of NIH and AHRQ application due date adjustments to accommodate scheduled federal system downtime. Grants.gov has a planned production system outage from Friday, September 23, 2022 at 12:01 AM ET to Thursday, September 29, 2022 at 11:59 PM ET (see [Grants.gov calendar](#)). Grants.gov will use this time to migrate their services to the Cloud. In response, NIH and AHRQ due dates that fall on or between September 22 and September 30, 2022 will move to October 3, 2022.

[NOT-HD-22-032](#) **Notice of Change to Foreign Eligibility and Application Due Date for RFA-HD-23-026 "NICHD Program Project Grants for HIV Research (P01 Clinical Trial Optional)"** The purpose of this Notice is to change the application due date to September 8, 2022 and to alert potential applicants that Non-domestic (non-U.S.) Entities (Foreign

Institutions) and Non-domestic (non-U.S.) components of U.S. Organizations are **not eligible** to apply for [RFA-HD-23-026](#)

## Notice of Special Interest (NOSI)

**[NOT-AI-22-056](#) Notice of Special Interest (NOSI): Opportunities for HIV Cure Interventions at the Time of ART Initiation.** This Notice of Special Interest (NOSI) serves to identify new opportunities for cure interventions administered during active HIV infection at or near the start of antiretroviral therapy (ART) or as a potential replacement for conventional ART, with the ultimate goal of achieving a sustained ART-free HIV remission. Under this NOSI, clinical trials are not allowed, but the use of samples from clinical trials supported by other funding mechanisms is encouraged. Studies in animal models, using HIV, SIV, or SHIV, are included in the scope. Therapeutic interventions should be evaluated in an in vitro cell-based model prior to in vivo studies.

Examples of strategies include but are not limited to:

- Strategies to eliminate HIV-infected cells
- Inhibiting latency establishment before/at ART start
- Preventing clonal expansion of reservoir cells
- Preventing wide HIV dissemination by employing HIV trafficking blockers
- Limiting reservoir seeding in sanctuary sites (e.g., B cell follicles)
- Optimizing and boosting the anti-HIV immune response

This notice applies to due dates on or after **January 7, 2023** and subsequent receipt dates through **September 7, 2025**.

**[NOT-OD-22-142](#) Notice of Special Interest (NOSI): Community-Based Participatory Research (CBPR) Initiative in Reducing and Eliminating Health Disparities with a focus on addressing diverse representation in research on Down syndrome (R21 Clinical Trial Optional).** The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for exploratory/developmental grant (R21) applications that are focused on community-based participatory research (CBPR) in DS to address health disparities and that meet programmatic objectives for the INCLUDE Project. Applicants must select the IC and associated FOA to use for submission of an application in response to this NOSI. The selection must align with the IC requirements listed in order to be considered responsive to that FOA. Non-responsive applications will be withdrawn from consideration for this initiative. In addition, applicants using NIH Parent Announcements (listed below) will be assigned to those ICs on this NOSI that have indicated those FOAs are acceptable and based on usual application-IC assignment practices. This notice applies to due dates on or after October 16, 2022 and subsequent receipt dates through March 17, 2025.

## Funding Opportunity Announcements (FOA)

### 1. Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-222](#)

**Type:** R01

**Application Due Date:** December 07, 2022; December 07, 2023; December 07, 2024 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The objective of this Funding Opportunity Announcement (FOA) is to support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic) multipurpose prevention technologies (MPTs). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy; or multiple non-HIV STI or HIV/STI MPTs in cis and trans males and females of all ages. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies using drug development, and formulation science supported by animal model testing. Also supported are biobehavioral and behavioral/social studies to identify MPT user-desired rheological and biophysical factors (look, feel, effectiveness, safety, and duration of action) and other behavioral/social factors that could promote increased MPT adoption and use.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

## 2. Global Implementation Science for Equitable Cancer Control (GlobalISE Cancer Control, U54 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-CA-22-019](#)

**Type:** U54

**Application Due Date:** November 08, 2022 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of the Global Implementation Science for Equitable Cancer Control (GlobalISE Cancer Control) Funding Opportunity Announcement (FOA) is to build implementation science centers in low- and middle-income countries (LMICs). This initiative will support implementation science research capacity-building activities, including research projects that identify, develop, and test innovative theory-based strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based cancer control interventions (e.g., programs, tools, policies, and guidelines) in LMICs. NCI will support several U54 Specialized Centers with transdisciplinary research teams meaningfully collaborating with key stakeholders (e.g., health systems, ministries of health, clinicians, and communities) that must include at least one PI or MPI from an LMIC-based institution. This initiative aims to foster LMIC-based implementation science programs to inform implementation of cancer control efforts in LMICs.

**Budget:** NCI intends to fund up to 4 awards, corresponding to a total of \$4 million, for fiscal year 2023. The number of awards is contingent upon the submission of a sufficient number of meritorious applications. Application budgets need to reflect the actual needs of the proposed project but must not exceed \$750,000 per year in direct costs. Project period of 5 years is required.

## 3. Contraceptive Development Research Center (P50 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-HD-23-029](#)

**Type:** P50

**Application Due Date:** December 01, 2022 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this funding opportunity announcement (FOA) is to support and facilitate multidisciplinary approaches towards the development of new and/or improved contraceptive methods for both men and women through the formation of a Contraceptive Development Research Center. This FOA also allows the inclusion of translational studies to facilitate the pre-clinical to clinical transition and increase the likelihood of clinical success. The Center will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research.

**Budget:** NIH intends to fund an estimate of up to 1 award, corresponding to a total of \$2,000,000, for fiscal year 2023. Future year amounts will depend on annual appropriations. Each Center should propose a budget that reflects the actual needs of the proposed projects and costs; the budget must not exceed \$1.3 million per year in direct costs, excluding third party F&A. The scope of the proposed project should determine the project period. The maximum period of performance is 3 years.

## 4. Early-Stage Therapy Development for ADRD (R61/R33 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-NS-22-059](#)

**Type:** R61/R33

**Application Due Date:** October 31, 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This funding opportunity announcement (FOA) encourages early-stage development of novel small molecule or biologic therapeutics for NINDS mission-relevant Alzheimer's and related dementias: frontotemporal degeneration (FTD), including Pick's disease and progressive supranuclear palsy), Lewy body dementias (LBD; including dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). This FOA covers four stages of early therapy discovery/development with each stage gated by go/no-go milestones. Applicants may enter the program at the stage appropriate to their research. The R61 phase supports preparatory research stages 1 -3: 1) development of in vitro and/or ex vivo assays that can support therapeutic screening efforts, 2) screening efforts to identify and characterize potential therapeutic agents, and 3) therapeutic optimization, pharmacodynamic and pharmacokinetic studies. The R33 phase supports stage 4, in vivo efficacy studies in an animal model of disease. This FOA supports research to enable competitive follow-on applications that meet the entry criteria for the Blueprint Neurotherapeutics Network, Blueprint Biologics, or other similar later-stage translational programs.

**Budget:** The following NIH ICs intend to commit the following amounts in FY23: \$3,750,000 total budget for year 1 to fund up to five awards contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NINDS & NIA. Direct costs cannot exceed \$500,000 in any one year. The total project period for a combined R61/R33 application submitted in response to this FOA may not exceed five years, with no more than four years for the R61 phase and no more than three years for the R33 phase. Applications proposing less than 4 stages of work are expected to request less time.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Division for Research Development (DRD)  
Stellenbosch Campus  
2041 Krottoa Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105